Epidemiology
Epidemiology has been defined as the "study of the distribution and size of disease problems in human populations, in particular to identify etiological factors in the pathogenesis of diseases and to provide the data essential for the management, evaluation and planning of services for the prevention, control and treatment of disease" (Everitt, 1998) . By quantifying disease occurrence and location, and using this information to identify etiological causes of the diseases by observing differences in exposures among areas with different distributions and size of the disease problem, modern epidemiologists have successfully identified serious risk factors associated with many diseases. For example, heart disease, skin cancer, and lung cancer have very clear etiological risk factors -obesity, sun, smoking -contributing to their occurrence. These were all identified through modern epidemiological studies.
The quantitative statistical tools of modern epidemiology have been well worked out both theoretically and for applied data analysis. Consider the simple case of trying to decide whether a particular exposure increases the odds of having a disease. Under a suitable controlled (and defined) experiment a set of cases (those with the disease) and controls (those without the disease but in all other senses similar to the cases) are obtained and the frequency of the exposure in the two groups is compared. This is easily displayed in the adjacent This has many well established theoretical advantages of which the most important is the clear interpretation of its value. If the 1 = OR (signified by a P value greater than 0.05) then we conclude the exposure is unrelated to the disease. On the other hand, if the or OR (signified by a P value less than or equal to 0.05) then we conclude the exposure is unrelated to the disease.
The odds ratio and many other classical statistical (e.g., vital statistics, life tables, logistic regression) and experimental design (e.g., cohort studies, case-control) methods have become part of the epidemiologists toolbox and are applied daily with great success in discovering etiological causes of disease. However, the complexity of data in molecular epidemiology, whose goal is the same as classical epidemiology of relating etiological exposures to disease, often will not fall into the same framework where the existing tools of epidemiology apply.
Molecular Biology
The term molecular biology was first described as "…an approach from the viewpoint of the so-called basic sciences with the leading idea of searching below the large-scale manifestations of classical biology for the corresponding molecular plan. It is concerned particularly with the forms of biological molecules and … is predominantly threedimensional and structural and … it must at the same time inquire into genesis and function" (Astbury, 1961) . In the intervening 40 years we have successfully gone below classical biology and amazingly unraveled the forms and structures of these biological molecules. Only now are we able to begin to uncover their genesis and function, and more excitingly, begin to apply this knowledge as biotechnology to benefit mankind in terms of advances in pharmaceuticals, medicine, and agriculture. The "Rate" of information transferred is routinely measured by RNA levels in cells using techniques such as microarrays. The histograms in the Box to the right in the figure above show how mRNA levels vary in genes across tissue types (or any other tissue samples).
In this illustration Gene A has high expression in both tissues, B is low in normal and high in tumor tissue, etc. The challenge for microarrays is that there will be upwards of 40,000 genes to analyze in a single experiment and not just three as this figure suggests.
Analyzing the effect of the Type and Rate of information transfer on biotechnology products present novel biostatistical challenges which this paper addresses.
Epidemiology and Molecular Biology: Statistical Challenges
The molecular epidemiology questions are similar in nature to classical epidemiology questions:
• How do different SNPs (type of information transferred) effect drug metabolism?
• How do different SNPs (type of information transferred) effect patient outcome?
• How do we select genes with similar expression profiles (rate of information transferred)?
• How do we select genes whose expression profiles (rate of information transferred) distinguish tissue subgroups?
However, the nature and complexity of the data pose serious problems to the analyst that cannot be overlooked, and that provide methodologists with exciting new problems to tackle. In this section I present three problems related to the data analysis of this data, and present (in brief outline) strategies my lab has taken to overcome them. The inclusion of this chapter in the book is hopefully to introduce the reader to a broad range of open problems in data analysis whose solutions might eventually be most efficiently solved by combining statistics, discrete mathematics, and computer science.
For the reader with little or no background in molecular biology I recommend two things.
First, read "How Genes Work" which is online and free at http://www.nigms.nih.gov, and "DNA: The Secret of Life" by James Watson and Andrew Berry (Knopf, 2003) as good simple introductions to the complexities of molecular biology. Second, find a biologist working on molecular epidemiology problems and work closely with them -attend their weekly lab meetings, provide service support for their standard data analyses to show you are a good citizen, and help solve 'their' problems. From these interactions you will begin to find the open data analysis problems that should be solved and therefore identify methodology that you can develop and will drive your research agenda. But before the non-epidemiologist reader knows what tools need to be developed (and I guarantee they are not the tools we think are needed or probably the tools we have developed thinking the world of molecular epidemiology will flock to our door) we need to know what the real problems being faced by the molecular biologist are.
Subgroup Identification
Under ideal conditions many statistical genetic methods have good power to detect phenotype-genotype relationships. However, the power decreases significantly in less than ideal situations. When possible we compensate for loss of power due to heterogeneous genetic etiology in the dataset (e.g., genotypic variation at locus A contributes to trait variation in some samples but not in others) by identifying subgroups within which statistical analyses are performed separately. In the following 2 x 2 table we see a statistically nonsignificant result indicating no relation between the genotype (SNP) and outcome: 
SNP Subgroup
This is a reasonable scenario in molecular epidemiology where the effect of a gene may be dependent on other genes not measured. Technically this is known as epistasis, or gene-gene interaction, and is becoming an important area of research in genetics and new methods to solve the computational complexity are very much needed.
We developed an approach for automatically identifying subgroups in genetic epidemiology data. By modifying the recursive partitioning algorithm for molecular data, we were able to increase the power to locate genes related to phenotype in simulation studies (Shannon, et al. 2001; Shannon, et al. 2002) . 
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In this model each subgroup has a separate regression line relating the outcome to the genetic factor ( . Fitting these models requires advanced partitioning algorithms.
Cluster analysis, which plays a prominent role in the statistical analysis of molecular data (Shannon, Culverhouse et al. 2003) , is another powerful data reduction tool used in molecular epidemiology to identify subgroups. The analytical goal of cluster analysis is to find subgroups such that samples (or genes) within a subgroup are more similar to each other than they are to samples (or genes) in different subgroups. Because molecular data often consists of large numbers of predictors, for example genes in a microarray or a large number of measured SNP's, the data must be reduced before the relationship between genes and phenotypes can be assessed. Putative relationships between clusters of samples and phenotypes need to be recognized as nothing more than hypotheses generated by clustering methods. Additional experiments must be done to statistically and biologically validate the relationships.
Unlike standard statistical methods such as the t-test and analysis-of-variance, statistical clustering does not have a probabilistic foundation. Because of this, there are no statistical tests or P values to determine how many subgroups are in the data and which subgroups are valid. We take two novel approaches to improve cluster analysis in molecular data analysis, and to formally test for the number of clusters in the data. We use consensus methods to combine results from multiple cluster analyses into a final, more stable cluster, and show that these final clusters indicate more clearly how many clusters exist in the data. We will also apply a probability model applicable to graphs to determine the significance level of the consensus model and allow the number of clusters to be statistically tested using a likelihood-ratio test (Shannon and Banks 1999; ).
Testing Covariates Against Molecular Variables
Analyses testing the relationship of covariates with molecular variables generally proceed in two steps. First, a statistical data reduction method such as hierarchical clustering is applied to the molecular variables (without reference to the covariate data) to identify sample subgroups. Second, covariate values are compared across the subgroups found in the first stage of analysis (e.g., if we split the data into subgroups identified by the dendrograms is one phenotype more likely to appear in one subgroup than in another).
This "two-stage" analysis is a very powerful paradigm, and has been used successfully in many microarray analyses, but is qualitative and provides no measures of association or statistical tests and P values.
We focus on using methods which directly test the statistical association of molecular data with clinical covariates (Shannon, Watson et al. 2002 
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Moving the analysis from raw data to pairwise distances we avoid the problem of an over-determined model and can begin to interpret complex genomic data for the epidemiologist. For example, highly correlated distances in the two matrices indicate the genetic and covariate data are related, while zero correlation indicates no relation. We are currently applying genetic algorithms in combination with Mantel correlation to identify subsets of genes that are most likely related to clinically meaningful covariates.
Selection of Molecular Variables
Perhaps the statistical problem getting the most attention in molecular data analysis is known as multiple testing. This occurs when multiple statistical tests have been performed to select genes from a microarray experiment which distinguishes sample types. In this case a P value is generated for each gene and genes are selected based on their ordering (e.g., 10, 100, or 1000 genes with the smallest P values). It is well known that this results in a significant increase in the number of false positives (i.e., number of genes declared significant when in fact they are not). Attempts to reduce this error are proposed based on Bonferroni, permutation, and false discovery rate adjustments.
However, these adjustments simply move the threshold for saying which genes to retain (e.g., 2, 65, 250 with the smallest adjusted P values versus 10, 100, or 1000 genes with the smallest unadjusted P values).
Current multiple adjustment techniques do not allow genes to be selected out of the order of the P values. In other words, genes with small fold changes (differences in the ratio of the mean expression values across two sample groups) can not be selected. This makes sense statistically but not biologically since many cases where a small change in a molecule results in drastic changes in phenotype. The figure shows a volcano plot display of 223 genes from a region on human chromosome 9 identified as possibly related to cytotoxicity in cells treated with a cancer drug ). The two dashed horizontal lines show arbitrary cutoff points for declaring genes significant depending on if they are above the horizontal line (bottom line is the unadjusted P value and the top line is the Bonferroni adjusted P value). We have developed a novel method (Li, Culverhouse et al. 2004) for gene selection based on fitting nonlinear quantile regression lines (the curved line following the shape of the data) and selecting those genes above this line as significant. The advantage of our approach is that we allow genes with small differences in expression level between groups (x-axis variable) to now be selected which would not be allowed with the adjustments described above.
Discussion
We believe that modern molecular data requires new methods of analysis to extract useful and valid information for biotechnology. In this brief paper we have identified three existing challenges of molecular data -subgroup identification, testing covariates against molecular variables, and selecting molecular variables -and discussed the approaches we have developed and routinely apply to overcome these challenges. We believe that researchers with skills in discrete mathematics and computer science, as well as in statistics, if working closely with molecular epidemiologists to solve their problems, can identify and make valuable methodological contributions.
